Clinical trial
Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC)
NCT04055038 is registered in ClinicalTrials.gov with Blokhin's Russian Cancer Research Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC)
- Lead sponsor
- Blokhin's Russian Cancer Research Center
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- September 1, 2019
- Completion date
- January 1, 2022
- Enrollment
- 164 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
brca1 mutation, brca2 mutation, chemotherapy, ovarian cancer, ovarian neoplasms, serous adenocarcinoma